-

Thermo Fisher Scientific and Structura Biotechnology Collaborate to Offer a Solution for Real-Time Cryo-EM Data Analysis

New Embedded CryoSPARC Live software to be made available by Structura and Thermo Fisher and designed to integrate with Thermo Fisher technology

HILLSBORO, Ore.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, and Structura Biotechnology Inc., a leading provider of cryo-EM data analysis software, today announced a collaboration to make available a new single particle analysis software solution, a version of Structura’s CryoSPARC Live, that is designed to integrate with Thermo Fisher’s Smart EPU software and cryo-transmission electron microscope (cryo-TEM) technology. The new solution, Embedded CryoSPARC Live, will be offered as a subscription.

Embedded CryoSPARC Live will enable cryo-electron microscopy (cryo-EM) users of all experience levels to obtain high-quality data while reducing the time it takes to transform raw data into high-quality 3D protein structures from days to hours.

Embedded CryoSPARC Live will offer real-time cryo-EM data analysis, including pre-processing (motion correction and CTF estimation), particle picking and extraction, streaming 2D classification, ab-initio 3D reconstruction, and streaming 3D refinement. This workflow will enable users to make decisions to optimize data acquisition and can be used as an input for Smart EPU plugins, which automatically adjust EPU data acquisition parameters in real-time.

“We’re thrilled to make this announcement with Structura Biotechnology as we work together to make cryo-EM more accessible, productive and easy to use,” said Trisha Rice, vice president and general manager of life sciences at Thermo Fisher Scientific. “This solution represents a major step forward in our plans to deliver a fully automated and intelligent cryo-EM imaging platform.”

“We’re excited to collaborate with Thermo Fisher Scientific and deliver a powerful solution that will help users in research and commercial settings move toward a more optimized and high-throughput cryo-EM workflow,” said Ali Punjani, CEO at Structura Biotechnology.

Embedded CryoSPARC Live will soon be available as an add-on for Smart EPU users and can be configured to connect to Thermo Fisher’s entire cryo-TEM portfolio, including the Thermo Scientific Tundra, Glacios and Krios Cryo-TEMs.

To learn more, visit our Embedded CryoSPARC Live webpage.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media:
Brianna Radicioni
Thermo Fisher Scientific
+1 617-390-3924
brianna.radicioni@thermofisher.com

Thermo Fisher Scientific Inc.

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media:
Brianna Radicioni
Thermo Fisher Scientific
+1 617-390-3924
brianna.radicioni@thermofisher.com

Social Media Profiles
More News From Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom